FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

Cristina Corno, Paola Perego, Michelandrea De Cesare et al.|Biochemical Pharmacology|2017

Cited by 44